Protalix BioTherapeutics (PLX) Net Equity Issued and Repurchased (2021 - 2025)

Protalix BioTherapeutics' Net Equity Issued and Repurchased history runs 4 years deep, the most recent figure standing at $4.0 million for Q2 2025.

• On a quarterly basis, Net Equity Issued and Repurchased changed N/A year-over-year to $4.0 million in Q2 2025; TTM through Dec 2025 was $6.8 million, a N/A change from a year earlier, with the FY2025 full-year figure at $6.8 million, up 87.87% from the prior year.
• Net Equity Issued and Repurchased grew to $4.0 million in Q2 2025 per PLX's latest filing, from $2.9 million in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $20.0 million in Q1 2023 and bottomed at $1.5 million in Q3 2022.
• The 4-year median for Net Equity Issued and Repurchased is $4.0 million (2023), against an average of $6.4 million.